Updated monthly
Drug Pricing & Access
Original pricing datasets, self-pay cost tracking, and insurance coverage analysis across branded and compounded GLP-1 medications.
Coming soon
Research Areas
Six domains of independent inquiry
Each research area maintains its own verification cadence, sourcing standards, and editorial review process. Publications are released as they meet our quality threshold.
FDA-sourced data
Comparative Efficacy
Head-to-head analysis of weight loss outcomes, A1C reduction, and cardiovascular endpoints across the GLP-1 receptor agonist class.
Coming soon
Label-verified
Safety & Tolerability
Adverse event profiles, contraindication mapping, and real-world tolerability data synthesized from prescribing information and published trials.
Coming soon
Real-time tracking
Pipeline & Approvals
Tracking next-generation molecules — orforglipron, survodutide, retatrutide, amycretin — from Phase III through FDA decision dates.
Coming soon
50+ providers tracked
Telehealth & Access
Provider landscape analysis, prescribing pattern data, and accessibility research across the GLP-1 telehealth ecosystem.
Coming soon
Federal & state
Policy & Regulation
FDA guidance analysis, compounding regulation, Medicare Part D coverage policy, and state-level access legislation tracking.
Coming soon
Published Datasets & Trackers
Live research publications
Original datasets and trackers currently maintained by The RX Index Research, each re-verified on its own update cadence.
GLP-1 Statistics 2026
Usage, cost & coverage data
GLP-1 Clinical Trial Demographics
17 FDA-label trials, 21,063 adults, versioned dataset
GLP-1 Clinical Trial Exclusion Criteria
17 pivotal trials, 15 normalized domains, exact thresholds
GLP-1 Patent Expiration Dates
U.S. FDA patent, exclusivity & Paragraph IV records
Generic Semaglutide Availability by Country
18-country verified market tracker
GLP-1 Lean Mass Loss by Drug
Trial-level body composition evidence map
GLP-1 Price & Access Tracker
Self-pay pricing, monthly re-verified
BALANCE Model Medicaid States
51-jurisdiction public-record tracker
GLP-1 Prior Auth by Insurer 2026
20-pathway insurer policy matrix
Medicare Part D GLP-1 Coverage by Plan
Route matrix, $50 Bridge, 2027 changes
Compounded GLP-1 Laws by State
51-jurisdiction 2026 legality tracker
ACA Marketplace GLP-1 Coverage by Carrier and State
26-of-300 baseline, July 2026 audit, BMI rules
Kansas SEHP GLP-1 Prior Authorization Requirements
BMI 35, May 2026 rule change, PA stats, primary sources
Medicaid Managed Care GLP-1 Coverage by Plan
62 plans, 11 states, 5 control models, 95.2% state-controlled
GLP-1 Telehealth Prescribing Practices: 2026 Data
49-site JAMA study, evidence crosswalk, standards, 82-record dataset
Medicare GLP-1 Prescriptions by State: 2024 Data
21.8M Part D claims, 51 jurisdictions, six-year panel, free download
GLP-1 FDA Label Changes: 14-Product Tracker
14/14 aspiration, 9 alopecia, 11-label bowel audit, 3 SI/B removals, full timeline
Counterfeit GLP-1 Incidents Tracker
32 regulator notice records, 12 jurisdictions, insulin in 4 countries, flagged lot table
GLP-1 Adverse Event Reports by Drug, Event Type, and Year
Published-study FAERS concordance, six downloadable datasets, version 1.0
GLP-1 Medicaid Coverage by State
2026 state-level dataset
Medicaid GLP-1 Coverage Map
State policy tracker
Medicare GLP-1 Bridge Tracker
Drugs, cost & eligibility
GLP-1 Employer Coverage Tracker
2026 employer plan data
Compounded GLP-1 Enforcement Tracker
FDA actions, 2026
GLP-1 Shortage Tracker
FDA package-level status, refill steps, and 2026 updates
GLP-1 Lawsuits & Enforcement Tracker
Litigation timeline
GLP-1 Pricing by Country
International price index
GLP-1 Manufacturer Financials
Quarterly revenue tracker
MACE in GLP-1 Cardiovascular Trials
Outcome trial explainer
GLP-1 Pancreatitis Risk
Symptoms & red flags
GLP-1 Demographics Data Dictionary
Field definitions and denominator rules
Research & Pricing Changelog
Every data revision, dated
Methodology
How we verify every claim
Every data point published in The RX Index Research follows a structured verification pipeline. We do not rely on press releases, manufacturer marketing materials, or secondary reporting.
01
Primary Source Identification
FDA prescribing information, ClinicalTrials.gov, and official manufacturer SEC filings.
02
Cross-Referencing
Every claim checked against at least two independent sources before publication.
03
Ongoing Verification
Pricing and availability data re-verified on a monthly cycle.
Source Hierarchy
Ranked by authority — higher tiers override lower
Tier 1Primary
FDA prescribing information & labels
Tier 2Primary
Published clinical trial results (peer-reviewed)
Tier 3Primary
ClinicalTrials.gov registry data
Tier 4Verified
Official manufacturer pricing pages
Tier 5Verified
SEC filings & investor presentations
Tier 6Secondary
Medical society guidelines (ADA, AHA, TOS)
Editorial Standards
Built on four principles
These standards apply to every piece of research we publish — without exception.
FDA-Sourced
All clinical claims verified against current FDA prescribing information and official labeling.
Conflict-Free
Research content is editorially independent — no sponsor influence, no pay-for-placement.
Primary-Source Verified
Findings trace directly to FDA records, supplement approval letters, and primary scientific sources.
Open Methodology
Our verification process, data sources, and analytical frameworks are fully documented.
Publications
Research publications launching soon
We're preparing our first wave of open-access research publications. Each will include full methodology documentation, source citations, and downloadable datasets where applicable.
Initial publications in development